An endogenous regulator of inflammation, resolvin E1, modulates osteoclast differentiation and bone resorption

British Journal of Pharmacology

Volumn 155, Issue 8, 2008, Pages 1214-1223

  Herrera, B S ^a,b   Ohira, T ^a   Gao, L ^a   Omori, K ^a   Yang, R ^c   Zhu, M ^a   Muscara, M N ^b   Serhan, C N ^c   Van Dyke, T E ^a   Gyurko, R ^a  

^a BOSTON UNIVERSITY   (United States)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Cell differentiation; Inflammation resolution; Lipid mediators; Osteoclasts

Indexed keywords

2 (2,6 DIHYDROXYHEXYL) 6 (3 HYDROXY 1,5 UNDECADIENYL)PYRIDINE; ANTIINFLAMMATORY AGENT; CELL SURFACE RECEPTOR; ICOSAPENTAENOIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LEUKOTRIENE B4; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MESSENGER RNA; PROTEIN KINASE B; PROTEIN P50; PROTEIN SUBUNIT; RESOLVIN E1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; BONE MARROW; BONE REMODELING; CELL COUNT; CELL CULTURE; CELL DIFFERENTIATION; CELL MEMBRANE; CELL SURVIVAL; CONTROLLED STUDY; DRUG MECHANISM; GROWTH INHIBITION; HUMAN; HUMAN CELL; INCUBATION TIME; INFLAMMATION; ISOTOPE LABELING; LIPOGENESIS; LIQUID CHROMATOGRAPHY; MALE; MOUSE; NEUTROPHIL; NONHUMAN; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RECEPTOR BINDING; TANDEM MASS SPECTROMETRY; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BONE RESORPTION; CELL DIFFERENTIATION; CELLS, CULTURED; DENTIN; EICOSAPENTAENOIC ACID; INFLAMMATION; LEUKOTRIENE B4; MICE; OSTEOCLASTS; RADIOLIGAND ASSAY;

EID: 57349138458     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/bjp.2008.367     Document Type: Article

References (30)

1. Arita M, Bianchini F, Aliberti J, Sher A, Chiang N, Hong S et al. (2005a). Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. J Exp Med 201: 713-722.
2. Arita M, Clish CB, Serhan CN (2005b). The contributions of aspirin and microbial oxygenase to the biosynthesis of anti-inflammatory resolvins: novel oxygenase products from omega-3 polyunsaturated fatty acids. Biochem Biophys Res Commun 338: 149-157.
3. Arita M, Ohira T, Sun YP, Elangovan S, Chiang N, Serhan CN (2007). Resolvin E1 selectively interacts with leukotriene B4 receptor BLT1 and ChemR23 to regulate inflammation. J Immunol 178: 3912-3917.
4. Arita M, Yoshida M, Hong S, Tjonahen E, Glickman JN, Petasis NA et al. (2005c). Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4, 6-trinitrobenzene sulfonic acid-induced colitis. Proc Natl Acad Sci USA 102: 7671-7676.
5. Boyle WJ, Simonet WS, Lacey DL (2003). Osteoclast differentiation and activation. Nature 423: 337-342.
6. Chellaiah MA, Soga N, Swanson S, McAllister S, Alvarez U, Wang D et al. (2000). Rho-A is critical for osteoclast podosome organization, motility, and bone resorption. J Biol Chem 275: 11993-12002.
7. Datta SR, Brunet A, Greenberg ME (1999). Cellular survival: a play in three Akts. Genes Dev 13: 2905-2927.
8. Flynn MA, Qiao M, Garcia C, Dallas M, Bonewald LF (1999). Avian osteoclast cells are stimulated to resorb calcified matrices by and possess receptors for leukotriene B4. Calcif Tissue Int 64: 154-159.
9. Garcia C, Boyce BF, Gilles J, Dallas M, Qiao M, Mundy GR et al. (1996). Leukotriene B4 stimulates osteoclastic bone resorption both in vitro and in vivo. J Bone Miner Res 11: 1619-1627.
10. Gyurko R, Shoji H, Battaglino RA, Boustany G, Gibson III FC, Genco CA et al. (2005). Inducible nitric oxide synthase mediates bone development and P. gingivalis-induced alveolar bone loss. Bone 36: 472-479.
11. Hasturk H, Kantarci A, Goguet-Surmenian E, Blackwood A, Andry C, Serhan CN et al. (2007). Resolvin E1 regulates inflammation at the cellular and tissue level and restores tissue homeostasis in vivo. J Immunol 179: 7021-7029.
12. Hasturk H, Kantarci A, Ohira T, Arita M, Ebrahimi N, Chiang N et al. (2006). RvE1 protects from local inflammation and osteoclast-mediated bone destruction in periodontitis. FASEB J 20: 401-403.
13. Hotokezaka H, Sakai E, Ohara N, Hotokezaka Y, Gonzales C, Matsuo KI et al. (2006). Molecular analysis of RANKL-independent cell fusion of osteoclast-like cells induced by TNF-alpha, lipopolysaccharide, or peptidoglycan. J Cell Biochem 101: 122-134.
14. Iwami-Morimoto Y, Yamaguchi K, Tanne K (1999). Influence of dietary n-3 polyunsaturated fatty acid on experimental tooth movement in rats. Angle Orthod 69: 365-371.
15. Kobayashi Y, Take I, Yamashita T, Mizoguchi T, Ninomiya T, Hattori T et al. (2005). Prostaglandin E2 receptors EP2 and EP4 are down-regulated during differentiation of mouse osteoclasts from their precursors. J Biol Chem 280: 24035-24042.
16. Liu XH, Kirschenbaum A, Yao S, Levine AC (2005). Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis t. Endocrinology 146: 1991-1998.
17. Nukaga J, Kobayashi M, Shinki T, Song H, Takada T, Takiguchi T et al. (2004). Regulatory effects of interleukin-1beta and prostaglandin E2 on expression of receptor activator of nuclear factor-kappaB ligand in human periodontal ligament cells. J Periodontol 75: 249-259.
18. Omori K, Naruishi K, Nishimura F, Yamada-Naruishi H, Takashiba S (2004). High glucose enhances interleukin-6-induced vascular endothelial growth factor 165 expression via activation of gp130-mediated p44/42 MAPK-CCAAT/enhancer binding protein signaling in gingival fibroblasts. J Biol Chem 279: 6643-6649.
19. Raisz LG (2005). Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest 115: 3318-3325.
20. Sakuma Y, Tanaka K, Suda M, Yasoda A, Natsui K, Tanaka I et al. (2000). Crucial involvement of the EP4 subtype of prostaglandin E receptor in osteoclast formation by proinflammatory cytokines and lipopolysaccharide. J Bone Miner Res 15: 218-227.
21. Schley PD, Jijon HB, Robinson LE, Field CJ (2005). Mechanisms of omega-3 fatty acid-induced growth inhibition in MDA-MB-231 human breast cancer cells. Breast Cancer Res Treat 92: 187-195.
22. Schwab JM, Chiang N, Arita M, Serhan CN (2007). Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature 447: 869-874.
23. Serhan CN (2007). Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. Annu Rev Immunol 25: 101-137.
24. Serhan CN, Clish CB, Brannon J, Colgan SP, Chiang N, Gronert K (2000). Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J Exp Med 192: 1197-1204.
25. Sugatani T, Hruska KA (2005). Akt1/Akt2 and mammalian target of rapamycin/Bim play critical roles in osteoclast differentiation and survival, respectively, whereas Akt is dispensable for cell survival in isolated osteoclast precursors. J Biol Chem 280: 3583-3589.
26. Sun D, Krishnan A, Zaman K, Lawrence R, Bhattacharya A, Fernandes G (2003). Dietary n-3 fatty acids decrease osteoclastogenesis and loss of bone mass in ovariectomized mice. J Bone Miner Res 18: 1206-1216.
27. Suzawa T, Miyaura C, Inada M, Maruyama T, Sugimoto Y, Ushikubi F et al. (2000). The role of prostaglandin E receptor subtypes (EP1, EP2, EP3, and EP4) in bone resorption: an analysis using specific agonists for the respective EPs. Endocrinology 141: 1554-1559.
28. Walsh NC, Crotti TN, Goldring SR, Gravallese EM (2005). Rheumatic diseases: the effects of inflammation on bone. Immunol Rev 208: 228-251.
29. Watkins BA, Li Y, Allen KG, Hoffmann WE, Seifert MF (2000). Dietary ratio of (n-6)/(n-3) polyunsaturated fatty acids alters the fatty acid composition of bone compartments and biomarkers of bone formation in rats. J Nutr 130: 2274-2284.
30. Yu X, Huang Y, Collin-Osdoby P, Osdoby P (2004). CCR1 chemokines promote the chemotactic recruitment, RANKL development, and motility of osteoclasts and are induced by inflammatory cytokines in osteoblasts. J Bone Miner Res 19: 2065-2077.